Answers are grounded in this paper and cite their sources.
Deferiprone (DFP), an iron chelator, is widely used to alleviate iron overload. However, its effects on bone metabolism remain incompletely understood. Herein, we demonstrated that DFP reduced osteoblast viability and in vitro mineralization. Interestingly, DFP delayed osteoclastogenesis, suppressed osteoclast marker expression, and appeared to influence iron efflux by upregulating Nrf2 and ferroportin-1. Although DFP effectively reduced iron accumulation in bone, it did not reverse persistent microstructural defects in the axial skeleton of β-thalassemic mice. Under high-iron conditions, DFP appeared to increase osteoclast turnover, leading to a transient accumulation of multinucleated osteoclasts followed by enhanced apoptosis. Collectively, our findings suggest a trade-off whereby reduced iron toxicity is accompanied by attenuated bone formation and resorption in β-thalassemic mice.
No takes yet. Share an insight, caveat, or question.
Aeimlapa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: